Mumbai, Feb. 15 -- Ganirelix Acetate Injection is a generic equivalent to the reference listed drug (RLD) Ganirelix Acetate Injection of Organon USA LLC.

It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.

Ganirelix Acetate Injection had estimated annual sales of $87 million in the U.S. (IQVIA MAT December 2023).

"Ganirelix is Lupin's first peptide-based injectable, strengthening the company's commitment to innovative healthcare solutions," the global pharma major said in a statement.

Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnol...